Transcat Share Price Today

Transcat Q2FY27 Results: Adj EPS $0.64 beats estimate, revenue up 18%

Transcat Q2FY27 adjusted EPS of $0.64 beat analyst estimates by 39.13%. Consolidated revenue rose 18% YoY to $97.1 million, exceeding forecasts by 5%. Service gross margins expanded 220 bps to 34.4%, driving 31% profit growth. Distribution adjusted operating income fell 9% due to lower-margin used equipment sales.

Transcat acquires Southeastern Biomedical for $12.8 million in cash

Transcat acquires Southeastern Biomedical for $12.8 million in cash. Deal effective August 31, 2026, subject to adjustments and holdbacks. Expands Transcat's biomedical calibration presence in southeastern US. Southeastern co-owners retain leadership roles post-acquisition.

Transcat appoints Roy Simmons as Chief Strategy and Corporate Development Officer

Transcat, Inc. has appointed Roy Simmons as Chief Strategy and Corporate Development Officer to lead its growth strategy and M&A efforts. Simmons brings over 20 years of experience from Pear Health Labs, GE Lighting, and Life Fitness. He will report to CEO Jaime Irick and focus on enhancing shareholder value through organic and inorganic growth.